The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial

J.G.F. Cleland*, J.P. Ferreira, B. Mariottoni, P. Pellicori, J. Cuthbert, J.A.J. Verdonschot, J. Petutschnigg, F.Z. Ahmed, F. Cosmi, H.P.B. La Rocca, M.A. Mamas, A.L. Clark, F. Edelmann, B. Pieske, J. Khan, K. McDonald, P. Rouet, J.A. Staessen, B. Mujaj, A. GonzalezJ. Diez, M. Hazebroek, S. Heymans, R. Latini, S. Grojean, A. Pizard, N. Girerd, P. Rossignol, T.J. Collier, F. Zannad, HOMAGE Trial Committees and Investigators

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

17 Citations (Web of Science)
Original languageEnglish
Pages (from-to)684-+
Number of pages15
JournalEuropean Heart Journal
Issue number6
Publication statusPublished - 7 Feb 2021


  • Spironolactone
  • Heart failure prevention
  • Fibrosis
  • Collagen markers

Cite this